Piermont Capital Management’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Piermont Capital Management’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-3,489	Closed	-$757K	–	267
2017 Q1	$757K	Sell	3,489 -1,111	-24%	-$159K	0.18%	193
2016 Q4	$426K	Buy	+4,600	New	+$518K	0.1%	240
2016 Q1	–	Sell	-1,281	Closed	-$420K	–	267
2015 Q4	$420K	Sell	1,281 -88	-6%	-$28.6K	0.13%	168
2015 Q3	$442K	Hold	1,369	–	–	0.14%	156
2015 Q2	$545K	Buy	+1,369	New	+$582K	0.16%	150

Other funds holding LUMO

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIM

Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

Piermont Capital Management's LUMO Position: Q2 2017 in Review

Piermont Capital Management sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q2 2017, closing a stake of 3,489 shares — an estimated $757K sold.

Piermont Capital Management first reported a position in LUMO in Q2 2015 and held it in 5 quarters. The position peaked at $757K in Q1 2017. 110 funds tracked by Wall St. Rank hold LUMO as of Q2 2017.

Piermont Capital Management reported no remaining Lumos Pharma, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
Piermont Capital Management sold 3,489 Lumos Pharma, Inc. Common Stock shares in Q2 2017, an estimated $757K.
Piermont Capital Management first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2015 and held it in 5 quarters.
Piermont Capital Management's Lumos Pharma, Inc. Common Stock position peaked at $757K in Q1 2017.
110 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q2 2017.

Based on Piermont Capital Management's 13F filing for Q2 2017, filed 11 Aug 2017.